Ventilator Associated Pneumonia (VAP) Pipeline Review, H1 2019 - ResearchAndMarkets.com
The "Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Ventilator
Associated Pneumonia (VAP) - Pipeline Review, H1 2019" drug
pipelines has been added to ResearchAndMarkets.com's
offering.
Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019,
provides comprehensive information on the therapeutics under development
for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete
with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline
guide also reviews of key players involved in therapeutic development
for Ventilator Associated Pneumonia (VAP) and features dormant and
discontinued projects. The guide covers therapeutics under Development
by Companies /Universities /Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and
Unknown stages are 8, 4, 8, 8, 1 and 1 respectively.
Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline
guide helps in identifying and tracking emerging players in the market
and their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Ventilator Associated Pneumonia (VAP) (Infectious
Disease). -
The pipeline guide reviews pipeline therapeutics for Ventilator
Associated Pneumonia (VAP) (Infectious Disease) by companies and
universities/research institutes based on information derived from
company and industry-specific sources. -
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
undisclosed stages. -
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities. -
The pipeline guide reviews key companies involved in Ventilator
Associated Pneumonia (VAP) (Infectious Disease) therapeutics and
enlists all their major and minor projects. -
The pipeline guide evaluates Ventilator Associated Pneumonia (VAP)
(Infectious Disease) therapeutics based on mechanism of action (MoA),
drug target, route of administration (RoA) and molecule type. -
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects. -
The pipeline guide reviews latest news related to pipeline
therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious
Disease)
Companies Mentioned
- Aridis Pharmaceuticals Inc
- AstraZeneca Plc
- Cumberland Pharmaceuticals Inc
- CytaCoat AB
- Destiny Pharma Plc
- Dong-A Socio Holdings Co Ltd
- Evaxion Biotech ApS
- MedImmune LLC
- Meiji Seika Pharma Co Ltd
- Merck & Co Inc
- Motif Bio Plc
- Nabriva Therapeutics Plc
- Polyphor AG
- Shionogi & Co Ltd
- Spero Therapeutics Inc
- Tetraphase Pharmaceuticals Inc
- Wockhardt Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bvccsn
View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005680/en/